Why I like Warfarin and Why You Should too

I am aware the love for Novel Oral Anticoagulants (NOACs) is growing and that warfarin is falling out of favour, especially in the setting of stroke prevention in atrial fibrillation or in the management of venous thromboembolism.  But hear me out on this one. Warfarin should stay and here’s why.

Continue reading Why I like Warfarin and Why You Should too

Advertisements

Single Pill Combination for Hypertension

This year for Hypertension Awareness Month and World Hypertension Day (May 17), I want to discuss about the role of single pill combination in the management of hypertension.  Single Pill Combination has been consistently recommended in various Hypertension Guidelines to assist with blood pressure control.  However, there is no great resource to guide available options of single pill combination in Ontario.

Continue reading Single Pill Combination for Hypertension

Talk Diabetes 2018 – Part I

Talk Diabetes 2018 was an education event presented by The Diabetes Education and Management Centre of Kingston Health Sciences Centre – Hotel Dieu Site on May 11, 2018. It was a day packed with many valuable contents to be shared among health care professionals looking for an updates in diabetes, especially with the recent release of the 2018 Diabetes Canada Clinical Practice Guidelines.  Here are some notes I took:

Continue reading Talk Diabetes 2018 – Part I

Mental Health Resources for Pharmacists

As we begin the dialogue this week on mental health awareness week, I also want to highlight some useful resources for pharmacists. Here are few of my favourites:

Continue reading Mental Health Resources for Pharmacists

Navigating Treatment Options for Venous Thromboembolism (VTE) Disease

A patient was presented at the ER with an unprovoked deep vein thrombosis (DVT). It  was eventually assessed to require indefinite oral anticoagulation therapy. He was started on rivaroxaban, a NOAC (novel oral anticoagulant).  Rivaroxaban as well as other NOACs  are recommended in the latest Chest guidelines as first line treatment options for venous thromboembolism disease. But the provincial drug plan does not recognize this update yet and is set up such that warfarin is the preferred agent for long term anticoagulation therapy. NOACs would only be reimbursed for the initial 6 months if treating conditions such as DVT.

Continue reading Navigating Treatment Options for Venous Thromboembolism (VTE) Disease